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sion of myasthenia gravis. The superiority of the trans-sternal and thoracoscopic surgical ap-
proaches is still being debated. The aims of this study are to compare postoperative
outcomes and neurologic outcomes between the two approaches and to identify prognostic
factors for complete stable remission (CSR).
Methods: Myasthenia gravis patients who underwent thymectomy with trans-sternal or thora-
coscopic approach in MahaRaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand between
January1, 2006 and December 31, 2013 were retrospectively reviewed. The endpoints were
postoperative outcomes and cumulative incidence function for CSR. The analysis was per-
formed using multilevel model, Cox’s proportional hazard model, and propensity score.
Results: Ninety-eight patients were enrolled in this study: 53 in the thoracoscopic group and 45
in the trans-sternal group. There were no significant differences between groups in composite
postoperative complications, surgical time, ventilator support days, and length of intensive
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acoscopic versus trans-sternal approthe thoracoscopic group. The CSR and median time to remission were not significantly
different between the two approaches. Prognostic factors for CSR were nonthymoma (hazard
ratio: 3.5, 95% confidence interval: 1.01e12.22) and presence of pharmacological remission
(hazard ratio: 24.3, 95% confidence interval: 3.27e180.41).
Conclusion: Thoracoscopic thymectomy is safe and provides good neurologic outcomes in com-
parison to the trans-sternal approach. Two predictive factors should be considered for CSR.
Further prospective studies with a larger sample size and longer follow-up period are war-
ranted to confirm these results.
Copyright ª 2016, Asian Surgical Association. Published by Elsevier Taiwan LLC. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
Myasthenia Gravis (MG) is an auto-immune disease associ-
ated with abnormal antibodies binding to the acetylcholine
receptors at the neuromuscular junction of the skeletal
muscle and causing the destruction and modification of the
neuromuscular junction.1 MG patients usually present with
a fluctuating degree of weakness of the skeletal muscle,
e.g., ocular, bulbar, respiratory muscles, and extremities.2
MG is strongly associated with thymic abnormalities.
About 10e21% of myasthenia patients have thymoma and
65e70% of those have thymic hyperplasia,3,4 whereas
20e47% of patients with a thymoma have MG.5e7 Previous
studies reported that 40e90% of MG patients achieved
remission after thymetomy versus 10e20% of those on
medication alone.8,9 Thymectomy can be completed ac-
cording to several approaches: trans-sternal, transcervical,
thoracoscopic, and subxyphoid. Trans-sternal thymectomy
has been the treatment of choice for MG patients according
to the Myasthenia Gravis Foundation of America (MGFA).
Recently, the thoracoscopic approach is not only widely
performed in early stage nonsmall cell lung cancer,10e13 but
also in thymectomy because of less pain, smaller scarring,
shorter length of hospital stay, and lower incidence of
myasthenia crisis in comparison to the trans-sternal
approach.14 Moreover, the rate of complete stable remis-
sion (CSR) is not inferior to what is obtained with the trans-
sternal approach.15e18
In our institute, thoracoscopic thymectomy has been
performed since 2006. There are no reports on the
comparative effectiveness between the two approaches in
Thailand. Therefore, this study was conducted to compare
postoperative outcomes and long-term neurologic outcomes
between thoracoscopic and trans-sternal approaches.
2. Methods
This study is a retrospective cohort study of MG patients
who underwent trans-sternal or thoracoscopic thymectomy
between January 1, 2006 and December 31, 2013 at
Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University,
Chiang Mai, Thailand. All patients were diagnosed by neu-
rologists using the MGFA clinical classification.19 Contrasted
computed tomography (CT) scan was performed in all
cases. Thymoma or malignant thymoma were diagnosed
and evaluated by expert thoracic radiologists from our
institute, using published criteria based on a CT scan. TheSiwachat S, et al., Comparative c
ach, Asian Journal of Surgery (20tumor can be identified as invasive by imaging that show
invasion of the surrounding tissue or great vessels.20 Pre-
operative blood antiacetylcholine receptor antibody titers
were not performed. The primary endpoint of this sec-
ondary analysis was postoperative outcomes [operative
time, blood loss, composite postoperative complications,
length of intensive care unit (ICU) and hospital stay, intu-
bation time, 28-day mortality]. The composite post-
operative complications include all postoperative
complications (diaphragmatic paralysis due to phrenic
nerve injury, atelectasis, cholinergic crisis, myasthenic
crisis, reintubation, and pneumonia). The secondary
endpoint was CSR defined as no signs or symptoms of MG
and no therapy for at least 1 year after surgery, except for
isolated weakness of eyelid closure.19 This study was
reviewed and approved by the Research Ethics Committee,
Faculty of Medicine, Chiang Mai University.
2.1. Surgical techniques
In our institute, selection criteria for thoracoscopic
approach for MG are one of following: (1) nonthymomatous
patients; or (2) small (< 3 cm) intrathymic thymoma.21,22
Trans-sternal thymectomy was performed with the stan-
dard technique. Thoracoscopic approach was performed
through the right side with three small incisions under
general anesthesia with isolated lung ventilation. The pa-
tient was placed in the left lateral decubitus position and
slightly supine, about 30. Right arm was abducted about
120 and the elbow was flexed over a padded L-screen for
exposure. A camera port was placed at the eight intercostal
space midaxillary line, and two working ports were placed
at the fourth intercostal space at the anterior axillary line
and sixth intercostal space at the posterior axillary line.
Prepericardial fat above the right phrenic nerve was
dissected. Thymic tissue and all anterior mediastinal fat
were also dissected away 1 cm anterior to the left phrenic
nerve. Arterial supplies and venous drainage were ligated
with metallic clips. Bilateral superior horns were dissected
with blunt technique. Thymus tissue and prepericardial fat
pad on left side were removed as much as possible or at
least reaching to left pleura. A right chest drain was placed
in the right pleural space. Extubation was performed
immediately after operation, in the recovery room or in the
intensive care unit depending on the consideration of the
anesthesiologists.
In cases of left side tumor, especially if > 3 cm, we
performed a trans-sternal approach. If the tumor was welllinical outcomes after thymectomy for myasthenia gravis: Thor-
16), http://dx.doi.org/10.1016/j.asjsur.2016.09.006
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used first. If the tumor was difficult to dissect, we con-
verted to a trans-sternal approach. However, in this study,
only the right sided-approach was performed, and no con-
versions were reported.
2.2. Data analysis
Categorical data were presented as frequency and percent.
Fisher’s exact test was used to compare categorical vari-
ables. Continuous data were presented as mean and stan-
dard deviation or median and interquartile range depending
on data distribution. Student t test or Wilcoxon’s rank-sum
test was used to compare continuous variables. Two-step
analysis was performed. Logistic regression was used to
calculate a propensity score (PS), which evaluates con-
founding by indication. The variables included in the model
for PS were age, sex, MGFA classification, time to surgery,
preoperative medication, myasthenic crisis within 1 month
before surgery, preoperative plasmapheresis, preoperative
conditions, preoperative forced vital capacity, and preop-
erative CT findings; the scorewas then divided into quintiles,
called PS-groups. A multilevel model stratified by PS-groups
was used for comparing the primary endpoint between
groups. For the secondary endpoint, firstly, a univariable
cox’s regression analysis for all variables was performed, and
variables having a p value < 0.1 were included in the
multivariable model with and without stratification by PS-
groups to identify independent prognostic factors for CSR.
A multicollinearity test was done. A p value < 0.05 was
considered to be statistically significant. The KaplaneMeier
failure estimate curve was used to demonstrate cumulative
incidence function for CSR and to compare the two groups.
All statistically analysis was performed using STATA program
version 13.0 (StataCorp, CS, TX, USA).
3. Results
Ninety-eight MG patients were enrolled in this study, 68
men (69%) and 30 women (31%); 53 patients (54.1%) un-
derwent thymectomy by thoracoscopic approach and 45
patients (45.9%) by trans-sternal approach. Demographic
and preoperative data are shown in Table 1. There was no
significant difference in terms of comorbid diseases except
for hypertension, severity of disease, preoperative plas-
maphreresis, operative parameters, and medication. The
trans-sternal group had more patients with hypertension
than in the thoracoscopic group. According to the preop-
erative CT scan, the number of patients who had thymoma
was significant higher in the trans-sternal group than the
thoracoscopic group. However, the PS (probability of
receiving certain treatment) showed a statistically signifi-
cant difference, therefore the overall preoperative patient
characteristics in each treatment group were different. For
this reason, a multilevel model stratified by PS-groups to
identify postoperative outcomes was performed (Table 2).
Perioperative findings and postoperative conditions are
reported in Table 3. The mean operative time was not
significantly different between groups. Patients in the
trans-sternal group had more intraoperative blood loss than
patients in the thoracoscopic group.Please cite this article in press as: Siwachat S, et al., Comparative c
acoscopic versus trans-sternal approach, Asian Journal of Surgery (201Postoperative complications occurred in 12 patients:
four patients in the trans-sternal group had left diaphrag-
matic paralysis and all of them were diagnosed with ma-
lignant thymoma, two patients in each group had
atelectasis, one of which in the trans-sternal group
required reintubation; one patient in the trans-sternal
group had cholinergic crisis, one patient in each group
had a MG crisis, and one patient in the thoracoscopic group
had pneumonia. No in-hospital mortality was observed in
this study. Most of the patients in this study had no post-
operative complications (89%) and could be immediately
extubated postoperatively (86%). There was no difference
in the length of ICU stay and ventilator support time be-
tween the two groups, although the trans-sternal group had
a significantly longer median length of hospital stay than
the thoracoscopic group. There was no statistically signifi-
cant difference between groups in the duration of venti-
lator support. Only three patients needed ventilator
support in the thoracoscopic group (1 day, 6 days, and 39
days, respectively), whereas, 11 patients in the trans-
sternal group needed it; five patients for 1 day, one pa-
tient for 2 days, one for 6 days, one for 13 days, one for 20
days, one for 39 days, and one for 40 days.
Study of postoperative outcomes analyzed by multilevel
model stratified by PS-groups (Table 2) showed no signifi-
cant differences between groups in terms of composite
postoperative complications, surgical time, ventilator sup-
port day, and length of ICU stay. Intraoperative blood loss
and length of hospital stay were significant less in the
thoracoscopic group.
For pathology results, because the mean age of the pa-
tient cohort was around 40 years, the most common thymic
pathology finding was fatty involution, not thymic
hyperplasia.23
The most common thymus pathology was fatty involution
(44 out of 98 cases, 45%; Table 4). The incidence of MG
associated with thymoma in this study was 29.6% (29 out of
98 cases). The number of patients diagnosed with fatty
involution was significantly higher in the thoracoscopic
group than in the trans-sternal group, whereas the number
of patients diagnosed with thymoma was higher in the
trans-sternal group. There were two patients diagnosed
with malignant thymoma in the thoracoscopic group, but
their preoperative CT finding reported thymic hyperplasia
and small-sized thymoma.
For the neurological outcomes after thymectomy, 27 of
98 patients (27.6%) had CSR at the most recent follow-up,
46 patients (46.9%) had pharmacological remission (PR),
and 20 patients (43.5%) had no CSR. The comparison of
neurological outcomes is shown in Table 5. The number of
patients who had medical reduction, achieved PR, and
achieved CSR were not significantly different between the
two groups. The median time at all events and the MGFA
classification at the end of follow-up were not different
between groups. The cumulative incidence function of CSR
at 48 months and 96 months was slightly higher in the
thoracoscopic group (27.07% vs. 19.24% and 60.38% vs.
40.88%, respectively, pZ 0.268; Figure 1). The median
follow-up time and long-term survival were not different
between groups. For long-term mortality, of the eight pa-
tients who died, two had thymoma and five had malignant
thymoma. In the thoracoscopic group, two patients (1linical outcomes after thymectomy for myasthenia gravis: Thor-
6), http://dx.doi.org/10.1016/j.asjsur.2016.09.006
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thenic crisis with septic shock at 4.6 years and 1.9 years
after surgery. In the trans-sternal group, two patients
(malignant thymoma) died from febrile neutropenia, severe
community acquired-pneumonia with septic shock at 6
months and 1 year after surgery, two patients (malignant
thymoma) died from a myasthenic crisis and septic shock at
1.5 months and 4.6 months after surgery, and two patients
(1 thymoma and 1 fatty involution) died from myasthenic
crisis with community acquired-pneumonia at 10 years and
10.3 years after surgery.
The identification of prognostic factors for CSR after
thymectomy is shown in Table 6. The presence of PR and
nonthymoma status were significant independentTable 1 Patient’s characteristics.
Variables
Sex
Female
Male
Age (y)
Underlying disease
Diabetes mellitus
Hypertension
Dyslipidemia
Thyroid disease
Others
MGFA classification
I
IIa
IIb
IIIa
IIIb
IV
V
Time to surgery (mo)
Preoperative prednisolone (mg)
Preoperative mestinon (mg)
Preoperative azathioprine (mg)
Myasthenic crisis within 1 mo before surgery
Preoperative plasmapheresis
Preoperative conditions
Respiratory failure
Bulbar involvement
Ocular involvement
Preoperative FVC
Preoperative CT findings
No mass
Thymic hyperplasia
Thymoma
Thymic cyst
Malignant thymoma
Probability of receiving a certain treatment (propensity score)a
Data are presented as n (%), mean  SD, or median  IQR (minemax)
CTZ computed tomography; FVCZ forced vital capacity; IQRZ inte
MGFAZ Myasthenia Gravis Foundation of America; SDZ standard de
a Propensity score calculated by logistic regression analysis consid
surgery, preoperative medication, myasthenic crisis within 1 month b
tions, preoperative FVC, and preoperative CT findings as determinan
Please cite this article in press as: Siwachat S, et al., Comparative c
acoscopic versus trans-sternal approach, Asian Journal of Surgery (20prognostic factors for CSR. However, after stratification by
PS, only PR was an independent prognostic factor for CSR.
The cumulative incidence function of CSR stratified by PR
and thymoma are shown in Figure 2. In the subgroup anal-
ysis of nonthymoma patients (69 patients), no independent
prognostic factor for CSR was found, possibly because of
the small sample size (low statistical power).4. Discussion
In 1987, after Kirschner24 reported the improvement of
clinical symptoms of MG after thymectomy, first performed
by Alfred Blalock in 1941,25 it has been widely accepted asThoracoscopic group
(nZ 53)
Transsternal group
(nZ 45)
p
0.190
13 (24.5) 17 (37.8)
40 (75.5) 28 (62.2)
41.5  14.2 38.9  14.9 0.388
9 (17.0) 4 (8.9) 0.371
1 (1.9) 8 (17.8) 0.011
3 (5.7) 4 (8.9) 0.700
6 (11.3) 2 (4.4) 0.282
3 (5.7) 2 (4.4) 1.000
0.699
3 (5.7) 4 (8.9)
17 (32.1) 10 (22.2)
28 (52.8) 23 (51.1)
0 1 (2.2)
4 (7.5) 5 (11.1)
0 0
1 (1.9) 2 (4.5)
12  31(1e192) 11  21 (1e48) 0.359
20  35 (0e60) 30  35 (0e60) 0.100
180  120 (0e540) 240  60 (0e540) 0.188
25  75 (0e100) 0  50 (0e150) 0.123
5 (9.4) 8 (17.8) 0.248
12 (22.6) 17 (37.8) 0.123
13 (24.5) 16 (35.6) 0.271
36 (67.9) 36 (80.0) 0.251
49 (92.5) 43 (95.6) 0.684
1790.5  655.6 1582  957.3 0.465
0.008
21 (39.6) 10 (22.2)
13 (24.5) 6 (13.3)
19 (35.9) 22 (48.9)
0 4 (8.9)
0 3 (6.6)
0.68  0.20 0.38  0.26 <0.001
.
rquartile range; maxZmaximum; minZminimum;
viation.
ering sex, age, underlying disease, MGFA classification, time to
efore surgery, preoperative plasmapheresis, preoperative condi-
ts of undergoing a thoracoscopic approach.
linical outcomes after thymectomy for myasthenia gravis: Thor-
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Table 2 Postoperative outcomes of the thoracoscopic group compared with the trans-sternal group: multilevel model
stratified by propensity score.
Variables Risk ratio Mean difference 95% CI p
Surgical time (min) d 9.93 .33 to 26.19 0.231
Blood loss d 60.43 102.74 to 18.11 <0.001
Composite postoperative complications 0.5 0.14e1.66 0.249
Ventilator support d (d) d 1.13 3.53 to 1.27 0.355
Lengths of ICU stay (d) d 0.10 0.42 to 0.21 0.521
Lengths of hospital stay (d) d 0.30 0.42 to e0.17 <0.001
CIZ confidence interval; ICUZ intensive care unit.
Table 3 Perioperative finding and postoperative conditions in the two groups.
Variable Thoracoscopic group
(nZ 53)
Transsternal group
(nZ 45)
p
Perioperative findings
Surgical time (min) 150.4  34.9 140.4  47.8 0.239
Blood loss (mL) 50  50 (0e300) 100  150 (0e600) 0.005
Postoperative conditions
No complication 49 (92.5) 38 (84.4) 0.336
Immediate extubation 48 (90.6)a 36 (80.0) 0.158
Left diaphragm paralysis 0 4 (8.9) 0.041
Atelectasis 2 (3.8) 2 (4.4) 1.000
Cholinergic crisis 0 1 (2.2) 0.459
Myasthenic crisis 1(1.9) 1 (2.2) 1.000
Reintubation 0 1 (2.2) 0.459
Pneumonia 1 (1.9) 0 1.000
ICU stay (d) 0  0 (0e39) 0  1 (0e40) 0.519
No ICU needed 41 (77.4) 32 (71.1) 0.521
Ventilator support (d)
Length of hospital stay (d)
6  38 (1e39)
nZ 3
7  4 (4e38)
2  12 (1e40)
nZ 11
10  4 (5e65)
0.570
<0.001
Data are presented as n (%), mean  SD, or median  IQR (minemax).
ICUZ intensive care unit; IQRZ interquartile range; maxZ maximum; minZ minimum; SDZ standard deviation.
a Two patients were extubated at recovery room.
Table 4 Pathologic report.
Variables Thoracoscopic group
(nZ 53)
Transsternal group
(nZ 45)
p
Pathologic reports 0.005
Fatty involution 31 (58.5) 13 (28.9)
Thymic hyperplasia 8 (15.1) 4 (8.9)
Thymoma 6 (11.3) 10 (22.2)
Malignant thymoma 2 (3.8) 11 (24.5)
Thymic involution 5 (9.4) 5 (11.1)
Thymic tissue 1 (1.9) 2 (4.4)
Data are presented as n (%).
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+ MODELstandard treatment of MG in addition to medical treat-
ment. The results of the most recently published random-
ized trial demonstrated that extended trans-sternal
thymectomy plus alternate day prednisone improved clin-
ical outcomes over a 3-year period in comparison to alter-
nate day prednisone alone in patients with
nonthymomatous MG.26 Many previous studies reportedPlease cite this article in press as: Siwachat S, et al., Comparative c
acoscopic versus trans-sternal approach, Asian Journal of Surgery (201that thymectomy in MG can achieve CSR.27e29 Over the
years, CSR rate progressively increased from 27e37.4% to
37e58.2% and 46e75% at 3 years, 10 years, and 15 years of
follow-up, respectively.28,30,31 There are several ap-
proaches for thymectomy: trans-sternal, transcervical,
unilateral thoracoscopic, bilateral thoracoscopic, sub-
xyphoid single portal, all with comparablelinical outcomes after thymectomy for myasthenia gravis: Thor-
6), http://dx.doi.org/10.1016/j.asjsur.2016.09.006
Table 5 Neurological outcomes after thymectomy.
Variables Thoracoscopic group
(nZ 53)
Transsternal group
(nZ 45)
p
Decreased medication 47 (88.7) 40 (88.9) 1.000
Median time of decreased medication (mo) 2.2  3.3 (0.1e76.6) 1.4  3.3 (0.5e26.1) 0.375a
Pharmacologic remission 27 (50.9) 19 (42.2) 0.422
Median time of pharmacologic remission (mo) 3.2  26.8 (0.5e76.8) 6.5  17.8 (0.7e110.4) 0.780a
Complete stable remission (CSR) 15 (28.3) 12 (26.7) 1.000
Median time of CSR (mo) 36.5  44.4 (8.7e76.8) 34.7  62.8 (8.3e110.4) 0.283a
MGFA at the end of follow-up 0.764
I 14 (26.4) 12 (26.7)
IIa 27 (50.9) 18 (40.0)
IIb 8 (15.1) 11 (24.5)
IIIa 2 (3.8) 2 (4.4)
Unknown 2 (3.8) 2 (4.4)
Follow-up time (mo) 0.128a
Mean  SD 41.8  29.9 54.9  39.3
Median  IQR
MineMax
38.8  43.0
0.3e118.5
56.1  64.1
0.3e125.2
Loss to follow-up 7 (13.2) 7 (15.6) 0.779
Death 2 (3.8) 6 (13.3) 0.18
Data are presented as n (%), mean  SD, or median  IQR (minemax).
IQRZ interquartile range; maxZmaximum; minZminimum; MGFAZ Myasthenia Gravis Foundation of America; SDZ standard
deviation.
a Log-rank test.
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+ MODELoutcomes.14e16,18,32,33 In the past, the most accepted
approach as standard technique was trans-sternal thymec-
tomy; however, after introducing thoracoscopic thymec-
tomy, this became the major approach for thymectomy in
MG patients because of the many advantages. However,
there are still discussions on the best side of approach, and
on unilaterality or bilaterality. In our institute, we perform
unilateral thoracoscopic thymectomy via the right-sided
approach because of several reasons. Firstly, the right
thoracic cavity is larger than the left side; therefore, it is
easier for dissection of the thymus gland. Secondly, supe-
rior vena cava is more clearly identified at the right side, so
it is rarely injured. Finally, superior vena cava is anFigure 1 Cumulative incidence function (CIF) of complete
stable remission comparing between the two approaches
(pZ 0.268). VATSZ video-assisted thoracoscopic surgery.
Please cite this article in press as: Siwachat S, et al., Comparative c
acoscopic versus trans-sternal approach, Asian Journal of Surgery (20excellent landmark to identify the innominate vein as well
as the venous tributaries to the thymus grand. Liu et al33
compared the long term outcomes of unilateral video-
assisted thoracic surgery extended thymectomy with the
bilateral approach in nonthymomatous MG and reported
that the unilateral approach had long-term CSR comparable
to the bilateral approach.
Preoperative CT scans showed a significant higher number
of thymoma patients in the trans-sternal group. In clinical
practice, the trans-sternal approach is standard.However, for
small thymomas less than 5 cm without surrounding tissue
invasion or Masaoka Class I or II, the thoracoscopic approach
was accepted.14,34e36 In our institute, if the thymoma was
identified by preoperative CT scan, the trans-sternal
approach was preferred to the thoracoscopic approach. This
could be a confounder by indication in the present analysis.
From theperioperative data, the surgical timewas slightly
longer in the thoracoscopic group than in the trans-sternal
group; whereas the thoracoscopic group had a significantly
less amount of blood loss than the trans-sternal group. The
reason might be that the trans-sternal approach has larger
incisions and requires the division of the sternum. Moreover,
the patients in the trans-sternal group had a thymoma more
frequently, and in some cases this needs a more aggressive
dissection such as en-bloc resection. The amount of blood
loss recorded in our study was rather small in comparison to
previous studies.33,37,38 In our study, a left diaphragmatic
paralysis was found only in the trans-sternal group cases that
were diagnosedwithmalignant thymoma; therefore, itmight
have occurred when dissecting the tumor away from the
phrenic nerve. The length of hospital stay was significant
longer in the trans-sternal group, something that could be
due to a more aggressive operation or dissection.linical outcomes after thymectomy for myasthenia gravis: Thor-
16), http://dx.doi.org/10.1016/j.asjsur.2016.09.006
Table 6 Prognostic factors for complete stable remission after thymectomy analyzed by univariable and multivariable Cox’s
regression analysis.
Variables Univariable analysis Multivariable analysis
HR 95% CI p HR 95% CI p
Age < 40 y 2.3 1.04e4.91 0.037 2.1 0.96e4.61 0.062
2.0a 0.78e4.97a 0.151a
Female 3.0 0.90e9.97 0.073 1.6 0.47e5.12 0.453
1.7a 0.45e6.17a 0.442a
Nonthymoma 4.2 1.24e13.98 0.021 3.5 1.01e12.22 0.049
3.2a 0.72e13.98a 0.126a
Pharmacological remission 29.6 4.01e218.80 0.001 24.3 3.27e180.41 0.002
21.8a 2.90e162.78a 0.003a
DM 1.1 0.32e5.59 0.906 d d d
Hypertension 1.1 0.27e4.85 0.855 d d d
Dyslipidemia 0.6 0.08e4.24 0.587 d d d
Thyroid disease 1.1 0.26e4.74 0.885 d d d
MGFA classification 1.0 0.68e1.39 0.886 d d d
Bulbar involvement 1.1 0.44e2.50 0.908 d d d
Ocular involvement 1.3 0.17e9.34 0.819 d d d
History of myasthenic crisis 1.1 0.44e2.15 0.959 d d d
Preoperative plasmapheresis 0.6 0.31e1.24 0.181 d d d
Time to surgery 1.0 0.99e1.02 0.254 d d d
VATS approach 0.6 0.30e1.40 0.268 d d d
Preoperative mestinon doses 1.0 0.99e1.01 0.181
Preoperative prednisolone doses 1.0 0.97e1.01 0.412
Preoperative azathioprine doses 1.0 0.98e1.01 0.211
CIZ confidence interval; DMZ diabetes mellitus; HRZ hazard ratio; MGFAZ Myasthenia Gravis Foundation of America; VATSZ video-
assisted thoracoscopic surgery.
a Stratified by propensity score.
Figure 2 Cumulative incidence function (CIF) of complete stable remission stratified by: (A) pharmacological remission (p value
0.002); and (B) thymoma (pZ 0.049).
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+ MODELRegarding the neurological outcomes, and the rate of
CSR, this study showed that thoracoscopic thymectomy was
comparable to trans-sternal thymectomy, consistent with
some previous studies.18,39 Other neurological outcomes
such as the rate of reduced medication andPlease cite this article in press as: Siwachat S, et al., Comparative c
acoscopic versus trans-sternal approach, Asian Journal of Surgery (201pharmacological remission were not different as well.
Although there was no statistically significant difference in
term of CSR between the two approaches, the trend of CSR
in the thoracoscopic thymectomy group was higher than in
the trans-sternal thymectomy.linical outcomes after thymectomy for myasthenia gravis: Thor-
6), http://dx.doi.org/10.1016/j.asjsur.2016.09.006
8 S. Siwachat et al.
+ MODELIn this study, CSR rate in the thoracoscopic group at 96
months (8 years) was 60.4%, whereas it was 75% at the 10-
year follow-up in the study by Manlulu et al.40 Jaretski
et al8 reported a CSR of 62% at 7.4 years and Lui et al33
demonstrated a CSR of 47% at 60 months. The CSR rate
after thymectomy via the right thoracoscopic approach in
our study is comparable to previous studies. However, a
longer follow-up time is needed to evaluate the neurolog-
ical outcomes with this approach.
The predictive factors of CSR are still inconclusive.41
Our results demonstrated two independent predictive
factors for CSR after thymectomy: nonthymoma and PR.
Patients who were diagnosed with nonthymoma had 3.5
chances to achieve CSR compared with thymoma patients.
Many previous studies reported the same
result.27,29,30,42,43 A nonthymoma diagnosis is one of the
prognostic factors for achieving CSR, although the result
was not confirmed by the analysis stratified by PS. The
possible reason is a mask effect from stratified with PS.
According to the definition of CSR and PR,19 patients who
had PR were those with no symptoms or signs of MG for at
least 1 year while they were still taking medications. Not
all patients who had PR will eventually experience CSR: in
our study, 43.5% of patients who had PR did not present
with CSR. Therefore, PR was included as one of the
possible prognostic variables in the multivariable model.
PR has never been previously reported as a predictive
factor for CSR after thymectomy in MG patients. However,
it is the strongest predictive factor in this study. An age
younger than 50 years has been reported as one of pre-
dictive factors for CSR30; however, we found that an age
younger than 40 years was a predictive factor for CSR in
univariable analysis but not in multivariable analysis. This
result could be explained by insufficient statistical power.
The limitation of this study is the retrospective nature of
data collection and the short follow-up time. There may be
some selection bias or confounders by indication as
described above. Because of the small sample size,
competing risk analysis among CSR, loss at follow-up, and
death was not performed. The CSR rate might be slightly
overestimated.
5. Conclusion
Thymectomy via the right thoracoscopic approach is a good
optional treatment for MG patients because it is less inva-
sive than the standard technique, has a decreased length of
hospital stay, and comparable neurological outcomes to the
trans-sternal approach. However, prospective randomized
controlled trials with a longer follow-up time are warranted.Acknowledgments
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